WATERTOWN, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ: ), a company committed to developing and commercializing treatments to help improve the lives of patients with severe retinal diseases, today announced that the company has awarded new employees as an out-of-company incentive award. Nonvested stock options granted 2023 Long-Term Incentive Plan pursuant to NASDAQ Listing Rule 5635(c)(4).

The Company granted six new employees stock options to purchase up to an aggregate of 54,600 shares of EyePoint Pharmaceuticals common stock. The stock options were granted on December 13, 2024. The grants were approved by the Compensation Committee and made as an incentive material to each employee entering employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The exercise price of the option awards is $7.46 per share, the closing price of EyePoint Pharmaceuticals common stock on December 13, 2024. The options have a tenor of 10-years and are 25% of the actual number of shares vesting on the first anniversary of the date of grant of the applicable employee and the remainder vesting in equal monthly installments over the following three years Vesting of Options Applicable Vesting Dates Subject to the employee's continued service with iPoint Pharmaceuticals by

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative treatments to help improve the lives of patients with chronic retinal diseases. The company's pipeline leverages its proprietary biodegradable Durasert E™ technology for sustained intraocular drug delivery. The Company's lead product candidate, DURAVYU™ (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases that combines vorolanib, a selective and patent-protected tyrosine kinase inhibitor. With biodegradable Durasert E™. DURAVYU is currently in Phase 3 global, pivotal clinical trials as a sustained-delivery treatment for wet AMD (NASDAQ: ), the leading cause of vision loss in people age 50 and older in the United States. and one is in a phase 2 clinical trial. In DME. Eyepoint expects full topline data from a Phase 2 clinical trial in DME in Q1 2025 and topline data from both pivotal Phase 3 trials in wet AMD in 2026.

Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, developed into Durasert E™ to potentially improve outcomes in severe retinal diseases. Proven Durasert ® drug delivery technology has been safely delivered to thousands of patient eyes in four US FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Vorolanib is exclusively licensed to EyePoint by Equinox Sciences, a Betta Pharmaceuticals affiliate, for topical treatment of all eye diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; It has not been approved by the FDA. The timeline for FDA approval and potential approval is uncertain.

For Eyepoint Pharmaceuticals:

Investors:
Christina Tartaglia
Accuracy AQ (first Stern (AS:) GO)
Direct: 212-698-8700
christina.tartaglia@precisionaq.com

Media Contact:
Amy Phillips
Green Room Communication
Direct: 412-327-9499
aphillips@greenroompr.com